<DOC>
	<DOCNO>NCT00006250</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know combination chemotherapy regimen effective non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness two different combination chemotherapy regimens treat patient stage III stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Newly Diagnosed Stage III Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival rate , progression free survival rate , clinical molecular remission rate , time treatment failure patient newly diagnose stage III IV follicular non-Hodgkin 's lymphoma treat chlorambucil , mitoxantrone , dexamethasone versus fludarabine , mitoxantrone , dexamethasone . - Compare efficacy tolerability regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord International Prognostic Index score [ low risk ( score 1 ) v intermediate low risk ( score 2 ) v intermediate high risk ( score 3 ) v high risk ( score 4 5 ) ] . Patients randomize one two treatment arm . - Arm I : Patients receive mitoxantrone IV day 1 , oral chlorambucil day 1-10 , oral dexamethasone day 1-5 . - Arm II : Patients receive mitoxantrone dexamethasone arm I fludarabine IV day 1-3 . Treatment continue every 4 week 4-8 course . Patients follow 3 , 6 , 12 month , every 6 month 1 year , annually thereafter clinical relapse . PROJECTED ACCRUAL : A total 500 patient ( 250 per arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose stage III IV follicular nonHodgkin 's lymphoma REAL classification grade I , II , III Treatment necessity indicate presence following : B symptom Bone marrow failure Bulky progressive disease Compression syndromes No CNS involvement PATIENT CHARACTERISTICS : Age : 18 70 Performance status : Not specify Life expectancy : Not specify Hematopoietic : No autoimmune hemolytic anemia active hemolysis Direct Coombs ' negative Hepatic : Alkaline phosphatase great 2.5 time upper limit normal ( ULN ) * Bilirubin great 2.5 time ULN* NOTE : *Unless attributable lymphoma Renal : Creatinine great 2.5 time ULN ( unless attributable lymphoma ) Cardiovascular : No severe cardiac failure Ejection fraction least 45 % Other : Not pregnant nursing Fertile patient must use effective contraception least 6 month study HIV negative No prior malignancy except carcinoma situ cervix squamous cell skin cancer No serious medical disease would limit lifespan ability tolerate chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>